SCHEMBL4909018

SCHEMBL4909018

N#Cc1c(Cl)nc(NC2CC2)nc1-c1cccc(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 10/20 0.56
ADORA2A P29274 6/20 0.55
ADORA2B P29275 3/20 0.53
CTSV O60911 1/20 0.48
PLAT P00750 1/20 0.48
CTSL P07711 1/20 0.48
CTSH P09668 1/20 0.48
CTSS P25774 1/20 0.48
CASP14 P31944 1/20 0.48
CTSK P43235 1/20 0.48
CASP6 P55212 1/20 0.48
CTSZ Q9UBR2 1/20 0.48
TRPA1 O75762 1/20 0.46
GRM5 P41594 2/20 0.43
ACHE P22303 1/20 0.42
ATM Q13315 1/20 0.40
MAP4K4 O95819 1/20 0.40
PIM1 P11309 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4899380 0.89 ADORA1 (0.53) ADORA1ADORA2AADORA2BCTSVPLAT
SCHEMBL4912631 0.85 ADORA2A (0.57) ADORA1ADORA2AADORA2BCTSLCTSS
SCHEMBL4899212 0.85 KDM1A (0.47) ADORA1ADORA2ACTSVPLATCTSL
SCHEMBL4906255 0.84 ADORA1 (0.47) ADORA1ADORA2AADORA2BCTSVPLAT
SCHEMBL4898439 0.84 KDM1A (0.52) ADORA1ADORA2AADORA2BCTSVPLAT
SCHEMBL4898316 0.83 CTSL (0.50) ADORA1ADORA2ACTSLCTSSCTSK
SCHEMBL4904144 0.83 CYP11B1 (0.39) ADORA1ADORA2AADORA2BCTSVPLAT
SCHEMBL4908292 0.82 KMT2A (0.56) ADORA1ADORA2AADORA2BACHE
SCHEMBL4911779 0.82 CTSK (0.40) ADORA1ADORA2ACTSVPLATCTSL
SCHEMBL4907249 0.82 KMT2A (0.41) ADORA1ADORA2AADORA2BCTSVPLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984377-A2 INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH Signal Pharmaceuticals LLC (US) 2008-10-29 EP disclosed
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 US disclosed
WO-2007084560-A2 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF ADORA1 529/4885ADORA2A 837/4885ADORA2B 953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.